ACG Case Rep J 6(6): e00075
Acute Dermato-Lymphangio-Adenitis Following Administration of Infliximab for Crohn's Disease
ABSTRACT
Tumor necrosis factor-α inhibitor (TNF-α) is frequently used for Crohn's disease and other autoimmune conditions. Increased risk of infection is an accepted adverse effect of TNF-α, and routine screening for potential infections are carried out before initiation of therapy. We report the case of a patient who developed a localized painful swelling near the injection site, which was diagnosed as acute dermato-lymphangio-adenitis due to filarial infection. This adds to the limited number of case reports on parasitic complications following TNF-α therapy.
REFERENCES
References
- 1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501. [[PubMed]
- 2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481–517. [[PubMed]
- 3. Sousa P, Allez M. Complications of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2015;31(4):296–302. [[PubMed]
- 4. Côté-Daigneault J, Bouin M, Lahaie R, Colombel J-F, Poitras P. Biologics in inflammatory bowel disease: What are the data?United Eur Gastroenterol J. 2015;3(5):419–28.
- 5. Lichtenstein GR, Feagan BG, Cohen RD, et al Infliximab for Crohn's disease: More than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490–501. [Google Scholar]
- 6. Shenoy R. Clinical and pathological aspects of filarial lymphedema and its management. Korean J Parasitol. 2008;46(3):119.
- 7. Behera M, Das S, Panda JK. Current Management: Filariasis. Medicine Update, 2017. Association of Physicians of India: Mumbai, India; 2017. [PubMed]
- 8. Addiss DG, Brady MA. Morbidity management in the global programme to eliminate lymphatic filariasis: A review of the scientific literature. Filaria J. 2007;6(1):2.
- 9. Rao RU, Nagodavithana KC, Samarasekera SD, et al A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis. 2014;8(11):e3281. [Google Scholar]
- 10. Weerasooriya MV. Elimination of Lymphatic Filariasis in Sri Lanka: Advances in Diagnosis and Management of Surveillance. Proceedings of the International Research Conference, General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka: 2017. [PubMed]
- 11. Lee HH, Song IH, Friedrich M, et al Cutaneous side‐effects in patients with rheumatic diseases during application of tumour necrosis factor‐α antagonists. Br J Dermatol. 2007;156(3):486–91. [[PubMed][Google Scholar]
- 12. Cocca S, Guarino M, Cicala M. Asymptomatic parasitic infection in a Crohn's disease patient on anti-TNFα therapy: An alert for our patients?J Crohn's Colitis. 2016;10(12):1455–6. [[PubMed]
- 13. Garner O, Ramirez-Berlioz A, Iardino A, Mocherla S, Bhairavarasu K. Disseminated nocardiosis associated with treatment with infliximab in a patient with ulcerative colitis. Am J Case Rep. 2017;18:1365–9.
- 14. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World J Gastroenterol. 2008;14(2):165.